{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:45:27Z","timestamp":1783975527532,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]},{"name":"European Joint Programme-Rare Diseases (EJP-RD) COCOS-IPF project","award":["EJPRD21-045"],"award-info":[{"award-number":["EJPRD21-045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-025-03146-4","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:45:03Z","timestamp":1740768303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Person-centred health outcomes in the routine care for people with progressive pulmonary fibrosis: the COCOS-IPF project\u2019s European survey on healthcare professionals\u2019 views and practices"],"prefix":"10.1186","volume":"26","author":[{"given":"Vivien","family":"Somogyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Delameillieure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silja","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"Van Bulck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Breuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli","family":"\u00dc\u00e7kuyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Nur","family":"T\u00f6reyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Stenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Mo\u011fulko\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Galvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomy","family":"Tonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Dobbels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"issue":"9","key":"3146_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3146_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","volume":"20","author":"M Kolb","year":"2019","unstructured":"Kolb M, Vasakova M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57.","journal-title":"Respir Res"},{"key":"3146_CR3","doi-asserted-by":"crossref","unstructured":"Lee JYT, Tikellis G, Corte TJ, Goh NS, Keir GJ, Spencer L et al. The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review. Eur Respir Rev. 2020;29(156).","DOI":"10.1183\/16000617.0125-2019"},{"issue":"1","key":"3146_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","volume":"18","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139.","journal-title":"Respir Res"},{"issue":"1","key":"3146_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12931-022-02143-1","volume":"23","author":"P Marijic","year":"2022","unstructured":"Marijic P, Schwarzkopf L, Maier W, Trudzinski F, Kreuter M, Schwettmann L. Comparing outcomes of ILD patients managed in specialised versus non-specialised centres. Respir Res. 2022;23(1):220.","journal-title":"Respir Res"},{"issue":"1","key":"3146_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12931-021-01815-8","volume":"22","author":"A Delameillieure","year":"2021","unstructured":"Delameillieure A, Vandekerkhof S, Van Grootven B, Wuyts WA, Dobbels F. Care programs and their components for patients with idiopathic pulmonary fibrosis: a systematic review. Respir Res. 2021;22(1):229.","journal-title":"Respir Res"},{"issue":"2","key":"3146_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1183\/13993003.01204-2015","volume":"47","author":"F Bonella","year":"2016","unstructured":"Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47(2):597\u2013606.","journal-title":"Eur Respir J"},{"issue":"26","key":"3146_CR8","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMp1011024","volume":"363","author":"ME Porter","year":"2010","unstructured":"Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477\u201381.","journal-title":"N Engl J Med"},{"issue":"2","key":"3146_CR9","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","volume":"204","author":"KI Aronson","year":"2021","unstructured":"Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, et al. Patient-centered Outcomes Research in interstitial lung disease: an official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021;204(2):e3\u201323.","journal-title":"Am J Respir Crit Care Med"},{"key":"3146_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1745-6215-13-132","volume":"13","author":"PR Williamson","year":"2012","unstructured":"Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132.","journal-title":"Trials"},{"key":"3146_CR11","unstructured":"http:\/\/cocos-ipf.com"},{"key":"3146_CR12","first-page":"427","volume-title":"Content analysis: an introduction to its methodology","author":"K Krippendorf","year":"2018","unstructured":"Krippendorf K. Content analysis: an introduction to its methodology. Fourth ed: SAGE Publications Inc; 2018. p. 427."},{"issue":"Suppl 3","key":"3146_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET handbook: version 1.0. Trials. 2017;18(Suppl 3):280.","journal-title":"Trials"},{"issue":"3","key":"3146_CR14","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","volume":"6","author":"G Eysenbach","year":"2004","unstructured":"Eysenbach G. Improving the quality of web surveys: the Checklist for reporting results of internet E-Surveys (CHERRIES). J Med Internet Res. 2004;6(3):e34.","journal-title":"J Med Internet Res"},{"key":"3146_CR15","doi-asserted-by":"crossref","unstructured":"Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK et al. Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on \u2018Feels, Functions, Survives\u2019. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency. Am J Respir Crit Care Med. 2024;209(6):647\u2013\u200969.","DOI":"10.1164\/rccm.202312-2213SO"},{"key":"3146_CR16","doi-asserted-by":"crossref","unstructured":"Brereton CJ, Wallis T, Casey M, Fox L, Pontopiddan K, Laws D et al. Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? ERJ Open Res. 2020;6(2).","DOI":"10.1183\/23120541.00120-2020"},{"key":"3146_CR17","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.2147\/JMDH.S421089","volume":"16","author":"R Biehl","year":"2023","unstructured":"Biehl R, Jeganathan N, Imperio M, Becerra BJ, Lopez D, Alismail A. A cross-sectional survey of pulmonologists Working at Non-ILD Centers in the United States. J Multidiscip Healthc. 2023;16:1939\u201342.","journal-title":"J Multidiscip Healthc"},{"issue":"1","key":"3146_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-021-01921-7","volume":"23","author":"JA de Andrade","year":"2022","unstructured":"de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, et al. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022;23(1):3.","journal-title":"Respir Res"},{"key":"3146_CR19","doi-asserted-by":"crossref","unstructured":"Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F et al. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? Eur Respir Rev. 2021;30(160).","DOI":"10.1183\/16000617.0026-2021"},{"issue":"1","key":"3146_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","volume":"21","author":"M Kreuter","year":"2020","unstructured":"Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, et al. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS(R) trials. Respir Res. 2020;21(1):36.","journal-title":"Respir Res"},{"key":"3146_CR21","unstructured":"EMA. Committee for Medicinal Products for Human use (CHMP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. Available at: http:\/\/www.emeaeuropaeu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003637.pdf. 27 July 2005, London."},{"key":"3146_CR22","unstructured":"FDA. Guidance for Industry: \u201ePatient-Reported Outcome Measures. Use in Medical Product Development to Support Labeling Claims. Available at: http:\/\/www.fdagov\/downloads\/Drugs\/Guidances\/UCM193282.pdf. December 2009."},{"key":"3146_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coph.2020.12.007","volume":"57","author":"KM Antoniou","year":"2021","unstructured":"Antoniou KM, Tsitoura E, Vasarmidi E, Symvoulakis EK, Aidinis V, Tzilas V, et al. Precision medicine in idiopathic pulmonary fibrosis therapy: from translational research to patient-centered care. Curr Opin Pharmacol. 2021;57:71\u201380.","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"3146_CR24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1513\/AnnalsATS.202008-1077ED","volume":"17","author":"MT Durheim","year":"2020","unstructured":"Durheim MT. Toward realizing the full potential of registries in interstitial lung disease. Ann Am Thorac Soc. 2020;17(12):1534\u20135.","journal-title":"Ann Am Thorac Soc"},{"key":"3146_CR25","unstructured":"https:\/\/www.eu-pff.org\/wp-content\/uploads\/2023\/02\/EUIPFF_Benchmark_Report_2020_Final.pdf"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-025-03146-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-025-03146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:45:10Z","timestamp":1740768310000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-025-03146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1186\/s12931-025-03146-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board (IRB) of KU Leuven (Belgium) waived the need for ethical approval as no personal information was collected. The study and the used QualtricsXM software adhere to the General Data Protection Regulation (GDPR) guidelines. Participation to the survey was voluntary and participants could decline to take part or leave the survey at any time. The information provided was kept completely confidential. The survey was analysed anonymously, and no e-mail addresses or IP addresses were collected as part of the survey. E-mail addresses were only used to distribute the survey and were not made available to the consortium. The data were only reported in an aggregated form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors explain that there are no issues relating to the journal\u2019s policies and confirm that the content of the manuscript has not been published, or submitted for publication elsewhere. No images are personal or clinical details of participants are presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Wim Wuyts: grants paid to institution from Roche, Sanofi, Alentis and Boehringer Ingelheim. - Liam Galvin and Steve Jones: unrestricted grants to EU-PFF from Boehringer Ingelheim, Roche, Trevi Therapeutics, Chiesi Pharmaceuticals, Bristol Meyer Squibb, Vicore Pharma, CSL Behring, and Ferrer.- Michael Kreuter: consulting fees from GSK, Boehringer, AstraZeneca, Pliant, and BMS. Yet, these authors declare that these disclosures did not influence the results and\/or discussion reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We hereby declare that AI has been used to ensure grammatical accuracy.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence"}}],"article-number":"81"}}